- Design
- Phase 3, randomised, double-blind, placebo-controlled trial, 114 centres
- Population
- 438 patients with advanced EGFR-mutated non-squamous NSCLC after third-generation EGFR TKI
- Primary outcome
- Progression-free survival and overall survival
- Effect
- PFS 6.8 vs 4.4 months, HR 0.52 (95% CI 0.41–0.66); OS 16.8 vs 14.0 months, HR 0.79 (0.62–1.01)
HARMONi randomised 438 patients with advanced non-squamous EGFR-mutated NSCLC that had progressed on a third-generation EGFR TKI, such as osimertinib. Patients received ivonescimab, a PD-1 and VEGF bispecific antibody, or placebo, each with carboplatin and pemetrexed. The trial was double-blind, and 70% of patients were Asian.
Median progression-free survival was 6.8 months with ivonescimab and 4.4 months with placebo (HR 0.52). Median overall survival was 16.8 and 14.0 months (HR 0.79), with a confidence interval that just crossed 1. Serious treatment-related adverse events were 28% against 15%.
EGFR-mutated lung cancer is common in Indian patients, and after osimertinib the options are limited to platinum doublets. Ivonescimab adds real progression-free time, but the survival benefit is not proven, toxicity is higher and regulatory status and access in India are not established. For now it is a trial or access-programme option rather than a new standard.
- Rebiopsy or send liquid biopsy at progression on osimertinib to look for targetable resistance
- Continue carboplatin-pemetrexed as the standard where ivonescimab is unavailable
- Discuss the progression-free survival gain and uncertain survival benefit honestly
- Monitor for bleeding and thrombotic events with VEGF-targeting agents
Why it matters
It is the first bispecific immunotherapy combination to show a progression-free benefit after EGFR TKI failure, where immunotherapy has usually disappointed.
Don't overread it
The overall survival result did not reach significance, and serious adverse events almost doubled.
The statistics, in plain English
Progression-free survival HR 0.52 (95% CI 0.41–0.66) is a clear effect. Overall survival HR 0.79 (0.62–1.01) suggests benefit, but the interval touches 1, so chance cannot be excluded. Overall survival was a co-primary endpoint, which makes the non-significant result important rather than incidental.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free